H
Haesook T. Kim
Researcher at Harvard University
Publications - 311
Citations - 17100
Haesook T. Kim is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 64, co-authored 283 publications receiving 15025 citations. Previous affiliations of Haesook T. Kim include Brigham and Women's Hospital & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal ArticleDOI
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth,Ken-ichi Matsuoka,Haesook T. Kim,Sean McDonough,Bhavjot Bindra,Edwin P. Alyea,Philippe Armand,Corey Cutler,Vincent T. Ho,Nathaniel S. Treister,Don C. Bienfang,Sashank Prasad,Dmitrios Tzachanis,Robin Joyce,David Avigan,Joseph H. Antin,Jerome Ritz,Robert J. Soiffer +17 more
TL;DR: Daily low-dose interleukin-2 was safely administered in patients with active chronic GVHD that was refractory to glucocorticoid therapy and was associated with preferential, sustained Treg cell expansion in vivo and amelioration of the manifestations of chronic GvHD in a substantial proportion of patients.
Journal ArticleDOI
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn,Erik A. Nelson,Mehrdad Mohseni,Fabrice Porcheray,Haesook T. Kim,Despina Litsa,Roberto Bellucci,Elke Raderschall,Christine Canning,Robert J. Soiffer,David A. Frank,Jerome Ritz +11 more
TL;DR: The findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo.
Journal ArticleDOI
Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation
Philippe Armand,Haesook T. Kim,Brent R. Logan,Zhiwei Wang,Edwin P. Alyea,Matt Kalaycio,Richard T. Maziarz,Joseph H. Antin,Robert J. Soiffer,Daniel J. Weisdorf,J. Douglas Rizzo,Mary M. Horowitz,Wael Saber +12 more
TL;DR: The validated and refined DRI can be used as a 4- or 3-group index, depending on the size of the cohort under study, for prognostication; to facilitate the interpretation of single-center, multicenter, or registry studies; to adjust center outcome data; and to stratify patients entering clinical trials that enroll patients across disease categories.
Journal ArticleDOI
Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis
TL;DR: Competing risks data analysis is discussed which includes methods to calculate the cumulative incidence of an event of interest in the presence of competing risks, to compare cumulative incidence curves in the absence of competing risk, and to perform competing risks regression analysis.
Journal ArticleDOI
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.
Emmanuel Zorn,Haesook T. Kim,Haesook T. Kim,Stephanie J. Lee,Stephanie J. Lee,Blair H. Floyd,Blair H. Floyd,Despina Litsa,Despina Litsa,Sankari Arumugarajah,Sankari Arumugarajah,Roberto Bellucci,Roberto Bellucci,Edwin P. Alyea,Edwin P. Alyea,Joseph H. Antin,Joseph H. Antin,Robert J. Soiffer,Robert J. Soiffer,Jerome Ritz,Jerome Ritz +20 more
TL;DR: It is indicated that patients with active cGVHD have reduced frequencies of Tregs but the function of these cells remains normal, and these findings support the development of new strategies to increase the number of T Regs following allogeneic hematopoietic stem cell transplantation.